

1           **COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of**  
2           **concern Spike antigens at 12 month post-infection**

3   **Pablo Garcia-Valtanen<sup>1†</sup>, Christopher M. Hope<sup>2,3†</sup>, Makutiro G. Masavuli<sup>1†</sup>, Arthur Eng Lip**  
4   **Yeow<sup>1</sup>, Harikrishnan Balachandran<sup>4</sup>, Zelalem A. Mekonnen<sup>1</sup>, Zahraa Al-Delfi<sup>1</sup>, Arunasingam**  
5   **Abayasingam<sup>4</sup>, David Agapiou<sup>4</sup>, Alberto Ospina Stella<sup>5</sup>, Anupriya Aggarwal<sup>5</sup>, Jason Gummow<sup>6</sup>,**  
6   **Catherine Ferguson<sup>7</sup>, Stephanie O'Connor<sup>8</sup>, Erin M. McCartney<sup>7</sup>, David J. Lynn<sup>9,10</sup>, Guy**  
7   **Maddern<sup>11</sup>, Eric J Gowans<sup>1</sup>, Benjamin AJ Reddi<sup>8</sup>, David Shaw<sup>7</sup>, Chuan Kok-Lim<sup>6,12,13</sup>, Stuart G**  
8   **Turville<sup>5</sup>, Michael R Beard<sup>13</sup>, Daniela Weiskopf<sup>14</sup>, Alessandro Sette<sup>14,15</sup>, Rowena A. Bull<sup>\*4</sup>,**  
9   **Simon C. Barry<sup>\*2,3</sup> and Branka Grubor-Bauk<sup>\*1</sup>**

10   <sup>1</sup> Viral Immunology Group, Adelaide Medical School, University of Adelaide and Basil Hetzel Institute  
11   for Translational Health Research, Adelaide, SA, Australia.

12   <sup>2</sup> Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia

13   <sup>3</sup> Women's and Children's Health Network, North Adelaide, SA, Australia

14   <sup>4</sup> School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia

15   <sup>5</sup> The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia

16   <sup>6</sup> Gene Silencing and Expression Core Facility, Adelaide Health and Medical Sciences, Robinson  
17   Research Institute, University of Adelaide, Adelaide, SA, Australia

18   <sup>7</sup> Infectious Diseases Department, Royal Adelaide Hospital, Central Adelaide Local Health Network  
19   Adelaide, SA, Australia

20   <sup>8</sup> Intensive Care Unit, Royal Adelaide Hospital, Central Adelaide Local Health Network and Adelaide  
21   Medical School, University of Adelaide, Adelaide, SA, Australia

22   <sup>9</sup> Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA  
23   5001, Australia

24   <sup>10</sup> Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA 5042, Australia.

25   <sup>11</sup> Discipline of Surgery, The University of Adelaide, Adelaide, SA 5000, Australia.

26   <sup>12</sup> Microbiology and Infectious Diseases Department, SA Pathology, Adelaide, SA, Australia

27   <sup>13</sup> Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide,  
28   SA, Australia

29   <sup>14</sup> Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla,  
30   CA, USA.

31   <sup>15</sup> Department of Medicine, Division of Infectious Diseases and Global Public Health, University of  
32   California, San Diego (UCSD), La Jolla, CA, USA

33   † These authors contributed equally.

34   \* **Corresponding Authors:** [branka.grubor@adelaide.edu.au](mailto:branka.grubor@adelaide.edu.au) ;

35   [simon.barry@adelaide.edu.au](mailto:simon.barry@adelaide.edu.au); [r.bull@unsw.edu.au](mailto:r.bull@unsw.edu.au)

36

37 **Abstract:**

38 **Background**

39 The duration and magnitude of SARS-CoV-2 immunity after infection, especially with regard  
40 to the emergence of new variants of concern (VoC), remains unclear. Here, immune memory  
41 to primary infection and immunity to VoC was assessed in mild-COVID-19 convalescents one  
42 year after infection and in the absence of viral re-exposure or COVID-19 vaccination.

43 **Methods**

44 Serum and PBMC were collected from mild-COVID-19 convalescents at ~6 and 12 months  
45 after a COVID-19 positive PCR (n=43) and from healthy SARS-CoV-2-seronegative controls  
46 (n=15-40). Serum titers of RBD and Spike-specific Ig were quantified by ELISA. Virus  
47 neutralisation was assessed against homologous, pseudotyped virus and homologous and  
48 VoC live viruses. Frequencies of Spike and RBD-specific memory B cells were quantified by  
49 flow cytometry. Magnitude of memory T cell responses was quantified and phenotyped by  
50 activation-induced marker assay, while T cell functionality was assessed by intracellular  
51 cytokine staining using peptides specific to homologous Spike virus antigen and four VoC  
52 Spike antigens.

53 **Findings**

54 At 12 months after mild-COVID-19, >90% of convalescents remained seropositive for RBD-IgG  
55 and 88.9% had circulating RBD-specific memory B cells. Despite this, only 51.2% convalescents  
56 had serum neutralising activity against homologous live-SARS-CoV-2 virus, which decreased  
57 to 44.2% when tested against live B.1.1.7, 4.6% against B.1.351, 11.6% against P.1 and 16.2%,  
58 against B.1.617.2 VoC. Spike and non-Spike-specific T cells were detected in >50% of  
59 convalescents with frequency values higher for Spike antigen (95% CI, 0.29-0.68% in CD4<sup>+</sup> and  
60 0.11-0.35% in CD8<sup>+</sup> T cells), compared to non-Spike antigens. Despite the high prevalence and  
61 maintenance of Spike-specific T cells in Spike 'high-responder' convalescents at 12 months, T  
62 cell functionality, measured by cytokine expression after stimulation with Spike epitopes  
63 corresponding to VoC was severely affected.

64 **Interpretations**

65 SARS-CoV-2 immunity is retained in a significant proportion of mild COVID-19 convalescents  
66 12 months post-infection in the absence of re-exposure to the virus. Despite this, changes in  
67 the amino acid sequence of the Spike antigen that are present in current VoC result in virus  
68 evasion of neutralising antibodies, as well as evasion of functional T cell responses.

69 **Funding**

70 This work was funded by project grants from The Hospital Research Foundation and Women's  
71 and Children's Hospital Foundation, Adelaide, Australia. MGM is THRF Early Career Fellow.  
72 BGB is THRF Mid-Career Fellow. This project has been supported partly with Federal funds  
73 from the National Institute of Allergy and Infectious Diseases, National Institutes of Health,

74 Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S. and  
75 Contract No. 75N9301900065 to A.S, D.W.

76

77 **KEYWORDS**

78 SARS-CoV-2, T cell immunity, memory B cells, antibody response, virus neutralisation,  
79 variant of concern, antigen drift.

80

## 81 **Evidence before this study**

82 We regularly searched on PubMed and Google Scholar in June-October 2021 using individual  
83 or combinations of the terms “long-term immunity”, “SARS-CoV-2”, “antigenic breadth”,  
84 “variant of concern” and “COVID-19”. We found studies that had assessed immune correlates  
85 at multiple time points after COVID-19 disease onset in convalescents, but not the antigenic  
86 breadth of T cells and antibodies and not in relation to VoC. Other immune studies in virus  
87 naive vaccinees, or vaccinated convalescents evaluated VoC-specific immunity, but not in  
88 convalescents that have not been vaccinated. In summary, we could not find long-term  
89 studies providing an in-depth evaluation of functionality of humoral and cell-mediated  
90 immunity, combined with addressing the adaptability of these immune players to VoC.

## 91 **Added value of this study**

92 The window of opportunity to conduct studies in COVID-19 convalescents (i.e. natural  
93 immunity to SARS-CoV-2) is closing due to mass vaccination programs. Here, in a cohort of  
94 unvaccinated mild-COVID-19 convalescents, we conducted a comprehensive, longitudinal,  
95 long-term immune study, which included functional assays to assess immune fitness against  
96 antigenically different VoC. Importantly, the cohort resided in a SARS-CoV-2-free community  
97 for the duration of the study with no subsequent re-exposure or infection. Our findings reveal  
98 a deeply weakened humoral response and functional vulnerability of T cell responses to VoC  
99 Spike antigens.

## 100 **Implications of all the available evidence**

101 This study provides a valuable snapshot of the quality of SARS-CoV-2 natural immunity and its  
102 durability in the context of a pandemic in which new variants continuously emerge and  
103 challenge pre-existing immune responses in convalescents and vaccinees. Our results serve as  
104 a warning that delays in vaccination programs could lead to an increase in re-infection rates  
105 of COVID-19 convalescents, caused by virus variants that escape humoral and cell-mediated  
106 immune responses. Furthermore, they reinforce the potential benefit of booster vaccination  
107 that is tuned to the active variants.

108

109

## 110 Introduction

111 Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected  
112 millions world-wide, causing respiratory coronavirus disease 2019 (COVID-19) and a global  
113 pandemic not seen in more than 100 years.<sup>1</sup> Rapid development and deployment of different  
114 COVID-19 vaccines and non-pharmaceutical interventions, such as hard and soft lockdowns  
115 are rapidly curbing numbers of daily new infections, hospitalisations and deaths in countries  
116 where these measures are implemented.<sup>2-7</sup> However, while vaccines represent the most likely  
117 way out of the pandemic, antibody responses and neutralising activity wane over the months  
118 following SARS-CoV-2 primary infection<sup>8,9</sup> as well as after immunization with current COVID-  
119 19 vaccines.<sup>10,11</sup> SARS-CoV-2 variants with mutations in the Spike protein which enable escape  
120 from host antibody responses, add to this problem in convalescents and vaccinees,<sup>12-19</sup> and  
121 have become a major obstacle to ending this pandemic. So far, four variants namely; B.1.1.7  
122 (also known as alpha or UK variant), B.1.351 (beta, RSA), P.1 (gamma, BRA) and B.1.617.2  
123 (delta, IND) have stood out for their ability to spread rapidly across different regions of the  
124 world [<https://covariants.org/>], hence earning them the denomination variant of concern  
125 (VoC).

126 After primary infection and in parallel with the antibody response, symptomatic COVID-  
127 19 convalescents generate a robust CD4<sup>+</sup> and CD8<sup>+</sup> memory T cell response which targets a  
128 wider range of antigens and epitopes than that covered by antibodies.<sup>20-24</sup> Importantly, the  
129 breath of SARS-CoV-2-specific T cell epitopes appears to be less sensitive to mutations present  
130 in VoC.<sup>25,26</sup> It is unclear to what extent T cells can protect from re-infection and progression  
131 to severe COVID-19. However, it is likely that T cell responses in convalescents, which target  
132 most SARS-CoV-2 antigens,<sup>20</sup> could afford some of level of protection for many months, even  
133 years. In fact, SARS-CoV-specific T cells can be detected in convalescents for almost two  
134 decades.<sup>27</sup>

135 While current vaccines are highly effective in preventing severe disease and death, and  
136 booster vaccinations may temporarily circumvent dwindling efficacy over time,<sup>28</sup> next  
137 generation vaccines, that can prevent virus transmission, are likely needed to end the  
138 pandemic.<sup>29,30</sup> Long-term studies of the evolution of immune correlates in COVID-19  
139 convalescents, where the immune system has encountered an active live virus infection in  
140 the presence of all its antigens, are necessary to elucidate the fine specificities and immune  
141 functionality of antibody and T cell responses. In particular, the adaptability of pre-existing  
142 immunity to mutated Spike antigens, present in VoC, is the key piece of information that is  
143 still unanswered.

144 Compared to the majority of the world, South Australia is in a unique position to  
145 undertake studies on mid- to long-term immunity of COVID-19 due to 1) early and strict  
146 border control measures with other countries, and other states within Australia, which were  
147 enforced by health authorities in 2020-21, thus eliminating local transmission of the virus in

148 the community, and 2) South Australia has maintained a high testing rate with a total test  
149 count of >2.2 M with only 899 positive cases of which only 9 were caused by unknown, locally-  
150 acquired contacts (accessed on 23/09/2021).<sup>31</sup>

151 We present a COVID-19 immunity study at 12 months after PCR confirmed SARS-CoV-2  
152 infection and in the complete absence of community transmission in a South Australian  
153 cohort of 43 mild COVID-19 convalescents. An in-depth evaluation of multi-isotype antibody  
154 responses, homologous pseudotyped virus, homologous and VoC live-virus serum  
155 neutralisation activity, RBD-specific B cell populations and Spike and non-Spike SARS-CoV-2  
156 specific CD8<sup>+</sup> and CD4<sup>+</sup> T cell immunity against ancestral and VoC antigenic epitopes, was  
157 undertaken. Results were compared to age- and gender-matched COVID-19 naïve, healthy  
158 individuals and to COVID-19 convalescent responses at 6 months after infection in the same  
159 cohort.

## 160 **Methods.**

### 161 **Study design and setting**

162 Individuals who tested positive in a nasopharyngeal swab SARS-CoV-2 RT-qPCR test in March-  
163 April 2020 at South Australian Pathology Services (Adelaide, Australia) were asked to  
164 participate in a longitudinal study to assess SARS-CoV-2-specific humoral and immune cell  
165 immune correlates (figure 1A). In this study, whole blood specimens from 43 participants (19  
166 male, 24 female) of (95% CI, 44.8-55.4) years of age (figure S1) who presented mild COVID-19  
167 symptoms according to NIH guidelines  
168 (<https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>) were  
169 sampled and processed at two time points 6 months apart after PCR positive test. All samples  
170 were coded and de-identified for analysis. None of the participants in this study tested  
171 positive for COVID-19 after their initial positive test. Age- and gender-matched seronegative  
172 (SARS-CoV-2 RBD and Spike) healthy controls (n=15) were included to provide baseline levels  
173 of different immune correlates (figure S1). Prior to this, a portion of our mild-COVID-19  
174 convalescents participated in a separate study that included serological, immunophenotyping  
175 and whole blood RNAseq analysis.<sup>32</sup>

176 Blood collection and processing at the Royal Adelaide Hospital, Women's and Children's  
177 Hospital, and The University of Adelaide were performed as previously described.<sup>33</sup> Blood was  
178 collected via phlebotomy in serum separator tubes (no additives) or  
179 ethylenediaminetetraacetic acid (EDTA) tubes and processed for serum, plasma and  
180 peripheral blood mononuclear cells (PBMCs) isolation.

181 Study protocols were approved by the Central Adelaide Clinical Human Research Ethics  
182 Committee (#13050) and the Women's and Children's Health Network Human research ethics  
183 (protocol HREC/19/WCHN/65), Adelaide, Australia. All participants provided written  
184 informed consent in accordance with the Declaration of Helsinki and procedures were carried  
185 out following the approved guidelines.

## 186 **SARS-CoV-2 RBD and Spike protein production**

187 Prefusion SARS-CoV-2 Spike ectodomain (isolate WHU1, residues 1-1208) with HexaPro  
188 mutations (kindly provided by Dr Adam Wheatley)<sup>34</sup> was used in ELISA. SARS-CoV-2 Spike  
189 transmembrane domain removed and a C-terminal His-tag (residues 1-1273) (kindly provided  
190 by Prof Florian Krammer)<sup>35</sup> was used for flow cytometric detection of Spike-specific B cells.  
191 SARS-CoV-2 RBD with C-terminal His-tag (residues 319-541; kindly provided by Prof Florian  
192 Krammer)<sup>35</sup> was used in ELISA and flow cytometry. Recombinant proteins were  
193 overexpressed in Expi293 cells (Thermo Fisher) and 72 hrs later purified by Ni-NTA affinity and  
194 size-exclusion chromatography.<sup>19</sup> Purified proteins were quantified using the Bradford  
195 protein assay (Bio-Rad) and analysed by SDS-PAGE and Western blot before being stored at -  
196 80°C. Recombinant RBD was biotinylated using the Avitag as described by the manufacturer  
197 (Genecopeia), while the Spike protein was biotinylated using an EZ-Link™ Sulfo-NHS-Biotin  
198 kit.

## 199 **SARS-CoV-2 RBD ELISA**

200 To normalise assay variance between individual experiments, standardized positive and  
201 negative controls were used. The threshold was set from sera collected from 40 healthy  
202 individuals prior to 2019 (mean + 2SD), while the positive control was sera from COVID-19  
203 convalescents, collected 12 weeks after positive COVID-19 PCR test. MaxiSorp 96-well plates  
204 were coated overnight at 4°C with 5µg/mL of recombinant RBD protein and blocked with 5%  
205 w/v skim milk in 0.05% Tween-20/PBS (PBST) at room temperature. Heat inactivated patient  
206 sera were serially diluted in blocking buffer, added and incubated for 2h at room temperature,  
207 followed by four washes in 0.05% PBST. Secondary antibodies were diluted in 5% skim milk in  
208 PBST as follows: Goat anti-Human IgG (H+L) Secondary Antibody, HRP (1:30,000; Invitrogen);  
209 Mouse Anti-Human IgG1 Fc-HRP (1:5000, Southern Biotech), Mouse Anti-Human IgG3 Hinge-  
210 HRP (1:5,000; Southern Biotech); Goat anti-human IgM HRP (1:5,000; Sigma): Goat anti-  
211 human IgA HRP antibody (1:5,000; Sigma) and incubated for 1 hour at room temperature,  
212 followed by four washes with PBS-T. Plates were developed with 1-Step™ Ultra TMB Substrate  
213 (ThermoFisher Scientific) and the reaction stopped with 2M sulphuric acid. Absorbance was  
214 measured at 450nm using Synergy HTX Multi-Mode Microplate Reader. SARS-CoV-2 Spike and  
215 RBD endpoint titers were calculated and expressed as area under the curve (AUC) using the  
216 mean optical density (OD) reading of the first dilution from healthy normal human sera as the  
217 baseline cut-off for seropositivity. AUC calculations were performed using Prism GraphPad.

## 218 **Detection of Spike- and RBD-specific memory B cells**

219 The staining method used for the detection of RBD and Spike memory B cells has been  
220 described previously.<sup>36</sup> In brief, biotinylated RBD and Spike proteins were  
221 incubated with Streptavidin-PE (SA-PE; Molecular probes; ThermoFisher Scientific) and  
222 Streptavidin-APC (SA-APC; BD Pharmingen) in a molar ratio of 4:1 and 2:1, respectively.  
223 Cryopreserved PBMCs were thawed rapidly in a 37°C water bath and washed with pre-  
224 warmed RPMI media supplemented with 2 mM L-glutamine, 50 IU/mL penicillin, 50 µg/mL

225 streptomycin, and 10% heat-inactivated fetal calf serum (Sigma) then washed twice. A  
226 maximum of  $1 \times 10^7$  cells were stained with Fixable Viability Stain 700 (FVS700) (BD Bioscience  
227 in a 1:1000 dilution), 5  $\mu$ L Human Fc block (BD Bioscience) per  $2 \times 10^6$  cells, 1  $\mu$ g/mL each of  
228 RBD and Spike tetramers, 5  $\mu$ L each of CD21 BV421, IgD BV510, CD10 BV605, CD19 BV711 and  
229 CD20 APC-H7, 8  $\mu$ L of IgG BV786, 2  $\mu$ L each of CD27 PE-CF594 and CD38 PE-Cy7, 2.5  $\mu$ L HLA-  
230 DR BB515 and 0.5  $\mu$ L CD3 BB700 (BD Bioscience). Cells were washed, resuspended in FACS  
231 wash buffer and the data acquired on BD FACSAria™ III. Data analysis was performed  
232 using FlowJo version 10.7.1 (TreeStar).

233

### 234 **SARS-CoV-2 pseudovirus neutralisation assay**

235 Pseudovirus neutralisation assays were performed as previously described.<sup>36</sup> In brief, SARS-  
236 CoV-2 pseudo-particles were generated by co-transfecting expression plasmids containing  
237 SARS-CoV-2 Spike (kindly provided by Dr Markus Hoffmann)<sup>37</sup> and the MLV gag/pol and  
238 luciferase vectors (kindly provided by Prof. Francois-Loic Cosset)<sup>38,39</sup> in CD81KO 293T cells  
239 (kindly provided by Dr Joe Grove),<sup>40</sup> using mammalian Calphos transfection kit (Takara Bio).  
240 Transfected cells were then incubated at 32°C, 5% CO<sub>2</sub> with the culture supernatants  
241 containing SARS-CoV-2 virus pseudoparticles (SARS-2pp) and harvested 48 hours post-  
242 transfection, concentrated 10-fold using 100,000 MWCO Vivaspin centrifugal concentrators  
243 (Sartorius) and stored at -80°C.

244 For neutralisation assays, SARS-2pp were diluted 50-fold and incubated for 1hr with heat-  
245 inactivated patient serum, followed by the addition of polybrene at a final concentration of  
246 4 $\mu$ g/mL (Sigma-Aldrich), prior to addition to 293T-ACE2 over-expressing cells (kindly provided  
247 by A/Prof Jesse Bloom).<sup>41</sup> 293T-ACE2 cells were seeded 24 h earlier at  $1.5 \times 10^4$  cells per well  
248 in 96-well white flat-bottom plates (Sigma-Aldrich). Cells were spinoculated at 800 g for two  
249 hours and incubated for two hours at 37°C, prior to media change. After 72 h, cells were lysed  
250 with a lysis buffer (Promega) and Bright Glo reagent (Promega) was added at a 1:1 ratio.  
251 Luminescence (RLU) was measured using CLARIOstar microplate reader (BMG Labtech).  
252 Neutralisation assays were performed in triplicate and outliers were excluded using the  
253 modified z-score method.<sup>42</sup> Percentage neutralisation of SARS-2pp was calculated as  $(1 - \text{RLU}$   
254  $\text{treatment/RLU no treatment}) \times 100$  and the half-maximum inhibitory serum dilution (ID<sub>50</sub>) was  
255 calculated for each sample. An ID<sub>50</sub> positive neutralisation cut-off of 22.61 was determined  
256 using ID<sub>50</sub> values obtained from 19 unexposed healthy participants (mean + 2 SD).<sup>36</sup> ID<sub>50</sub> for  
257 serum was calculated using a non-linear regression model (GraphPad Prism).

### 258 **SARS-CoV-2 live-virus neutralisation assay**

259 HEK-ACE2/TMPRSS cells (Clone 24)<sup>43</sup> were seeded in 384-well plates at  $5 \times 10^3$  cells/well in  
260 the presence of the live cell nuclear stain Hoechst-33342 dye (NucBlue, Invitrogen) at a  
261 concentration of 5% v/v. Two-fold dilutions of patient plasma samples were mixed with an  
262 equal volume of SARS-CoV-2 virus solution ( $1.25 \times 10^4$  TCID<sub>50</sub>/ml) and incubated at 37°C for  
263 1 hour before adding 40  $\mu$ L, in duplicate, to the cells (final MOI = 0.05). Viral variants used

264 included the key variants of concern; Alpha (B.1.1.7), Beta (B.1.351), Gamma (P1) and Delta  
265 (B.1.617.2), as well as ‘wild-type’ control virus (A.2.2) from clade A and presenting no aa  
266 mutations in Spike (similar to Wuhan ancestral variant). Plates were incubated for 24 hours  
267 post infection and entire wells were imaged by high-content fluorescence microscopy, cell  
268 counts obtained with automated image analysis software, and the percentage of virus  
269 neutralisation was calculated with the formula:  $\%N = (D - (1 - Q)) \times 100 / D$ , as previously  
270 described.<sup>43</sup> An average  $\%N > 50\%$  was defined as having neutralising activity.

## 271 **SARS-CoV-2 and CMV peptide megapools**

272 SARS-CoV-2 and CMV peptide megapools were kindly provided by Prof Alessandro Sette (La  
273 Jolla Institute of Immunology, CA, USA).<sup>23</sup> For SARS-CoV-2 whole proteome, CD8-specific  
274 peptide pools, 628 peptides restricted to the 12 most common HLA-A and HLA-B alleles and  
275 partially covering the sequences of nsp1, nsp2, PLpro, nsp4, nsp6, nsp7, nucleocapsid  
276 phosphoprotein, 3CL, nsp8, nsp9, nsp10, nsp14, RdRpol, Hel, nsp15, nsp16, surface  
277 glycoprotein, ORF3a, ORF10, ORF6, ORF7a, ORF8, envelope protein, and membrane  
278 glycoprotein were predicted *in silico* as previously described.<sup>21</sup> Peptides were divided into two  
279 separate megapools, CD8\_A and CD8\_B. In Spike peptide pool, 15-mer peptides overlapping  
280 by 10 amino acids and covering the entire Spike protein sequence were used (total of 253  
281 peptides). For the non-Spike SARS-CoV-2 CD4 megapool 221 15-mer restricted to seven  
282 common HLA-DR (Class II HLA) alleles and covering the entire SARS-CoV-2 proteome, except  
283 for the Spike protein, were predicted *in silico* as described previously.<sup>21</sup> The CD8 and CD4  
284 human Cytomegalovirus (CMV) megapools used as a virus-positive control response consist  
285 of HLA-restricted 204 and 141 peptides.<sup>44</sup> All peptides were synthesized and resuspended in  
286 DMSO at 1 mg/ml.

## 287 **Activation induced cell marker (AIM) T cell assay**

288 Thawed PBMCs were rested for 2 hours at 37°C, 5% CO<sub>2</sub> in complete RPMI (cRPMI) medium  
289 (40 U/mL penicillin, 40 µg/mL streptomycin, 2 mM L-Glutamine) with 5% (v/v) heat-  
290 inactivated human AB serum. Cells were then plated at 10<sup>6</sup> PBMC/well in u-bottom 96-well  
291 plates and stimulated with 1 µg/mL of different SARS-CoV-2- megapools. Combined CD4 and  
292 CD8 cytomegalovirus (CMV) megapool (1 µg/mL) and PHA 10µg/mL (Sigma Aldrich), were  
293 included as positive controls. An equimolar amount of dimethyl sulfoxide (DMSO, vehicle) was  
294 used as a negative control. PBMC were stimulated for 24 h at 37°C, 5% CO<sub>2</sub>, washed and  
295 stained with Zombie Green Fixable Live/Dead Stain (L/D, Biolegend) for 20 min, RT, in the dark.  
296 Cells were then washed and stained with (CD3 BUV737, CD4 BUV496, CD8 BUV395, CD14  
297 FITC, CD19 FITC, CD45RA BV650, CCR7 (CD197) APC, CD69 PE, CD134 (OX40) PE-Cy7, CD137  
298 (41-BB) BV421) for 20min, at room temperature in the dark. Fluorescence minus one (FMO)  
299 control for antigens: CD45RA, CCR7, CD134, CD69 and CD137 were added to PHA stimulated  
300 cells. PBMC were washed and FACS Fix (0.4%PFA, 20g/L Glucose, Sodium Azide 0.02% in PBS)  
301 was added for 20 min at room temperature, in the dark. Fixed cells were washed,  
302 resuspended in FACS wash buffer and data was acquired on BD FACS Symphony. Data analysis

303 was performed using FCS Express™ (DeNovo Software, Pasadena, CA, USA). All percentages  
304 of activated cells were calculated subtracting unspecific DMSO background for each cell  
305 phenotype and individual patient.

#### 306 **Variant of concern Spike-specific peptide pools.**

307 SARS-CoV-2 Spike PepTivator® protein pools (Miltenyi Biotec, Gladbach, GER) were utilised to  
308 test immune reactivity of COVID-19 convalescent T cells to mutated Spike epitopes present in  
309 four VoC.<sup>26,45</sup> All peptide pools consisted of 15-mer peptides with 11 aa overlap covering Spike  
310 protein sequences affected by mutations in each VoC. Four VoC peptide pools corresponding  
311 to mutated Spike sequences in SARS-CoV-2 variants B.1.1.7, B.1.351, P.1 and B.1.617.2 (34,  
312 30, 41 and 32 peptides, respectively) and four corresponding control/reference pools with  
313 Wuhan aa sequences were compared in parallel along with whole Spike peptide pool as  
314 positive control (pool described above). Mutations and deletions represented in mutated  
315 pools are summarized in Table S1. For the assays, lyophilised peptides were resuspended in  
316 sterile miliQ water as per the manufacturer's instructions at 30 nM (50 µg/mL), aliquoted and  
317 stored at -80 °C until used.

#### 318 **Spike-specific T follicular helper cell quantification and intracellular cytokine staining in** 319 **Spike high responder convalescents.**

320 According to AIM assay results, convalescents with Spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell  
321 frequencies above the mean plus 3\*standard deviations in the healthy control group were  
322 identified. Double responders (meeting criterion for both CD4<sup>+</sup> and CD8<sup>+</sup> T cells) and high CD4<sup>+</sup>  
323 with available PBMC samples were selected (n=15) for further analysis. Following methods  
324 similar to other published prior to this study,<sup>46</sup> PBMCs were thawed and prepared for cell  
325 culture as described for the AIM assay. Cells were pre-treated with 0.555 µg/mL of anti-CD40  
326 blocking antibody (HB14, Miltenyi Biotec) for 15 min. Then, peptide pools were added to a  
327 final concentration of 1 µg/mL (making anti-CD40 concentration 0.5µg/mL for the remainder  
328 of the stimulation period). After a 24 hr incubation 2 µM GolgiStop™ (containing monensin,  
329 BD, 554724) and 1µg/mL GolgiPlug™ (containing Brefeldin A, BD, 555029) were added to the  
330 cells and incubated for an additional 4 hrs. Cells were then co-incubated with Fixable Viability  
331 stain 780 (BD) and Fc Block (BD) for 20 min, RT, in the dark, washed with FACS buffer solution  
332 and stained with surface stain mix (CD3 BUV737, CD4 BUV496, CD8 BUV395, CXCR5 BUV563,  
333 CD14 APC-Cy7, CD20 APC-Cy7) for 20 min, RT, in the dark. Cells were washed with PBS and  
334 subsequently fixed and permeabilized with Cytofix/Cytoperm™ (BD, 51-2090KZ) for 20 min,  
335 RT, in the dark. Cells were then washed with Perm/Wash™ (BD, 51-2091KZ) and stained with  
336 ICS stain Mix (CD154 PE, IFNγ PE-Cy7, TNFα APC, PRF1 FITC, IL-2 BV711, GZMB BV421) for 20  
337 min, RT, in the dark. Cells were then washed twice with Perm/Wash™ and once with PBS.  
338 Finally, cells were resuspended in PBS and kept at 4 °C until data was acquired on BD FACS  
339 Symphony. Data analysis was performed using FCS Express™ (DeNovo Software, Pasadena,  
340 CA, USA).

341 Fold-change values in ICS data for VoC peptide pools and reference pools were calculated as  
342 follows: Fold Change (MUT/REF)= VoC pool % of cytokine positive cells/ Reference pool % of  
343 cytokine positive cells. From fold-change values between 0 and 1, negative fold-change values  
344 were calculated: Negative fold= 1/(Fold change [MUT/REF]).

#### 345 **Statistics, replicates and sample-size estimation.**

346 All mild-COVID-19 patient samples available at the time points reported in the study from the  
347 South Australian cohort (n=43) were used in this study and, therefore, no *pre hoc* power  
348 calculations were carried out to determine the sample size. A sufficient number of healthy  
349 controls (n=15) were recruited to establish meaningful comparisons and assay cut-off and  
350 baseline levels consistent with current literature. Additional healthy controls (sampled prior  
351 to 2019) were used to validate serological, virus neutralisation and B cell staining assays (see  
352 Methods section). All statistical analyses were performed using GraphPad Prism 9.0.0 (San  
353 Diego, CA, US). No assumptions were made about the distribution of the data sets; non-  
354 parametric tests were used in all cases for comparisons. Accordingly, two-tailed Mann-  
355 Whitney's or Welch's tests were applied for pair-wise comparisons or Krustal-Wallis test for  
356 unpaired comparisons (HC vs patient data) of antibody and T cell frequency data. A non-linear  
357 regression model was used to calculate individual patient ID<sub>50</sub> values from corresponding  
358 pseudovirus particles neutralisation assay data.<sup>47</sup> A mixed-effects analysis was performed to  
359 carry out all pair-wise comparisons in memory B cell frequency data. Conservative multiple  
360 comparisons corrections were not applied in statistical analysis in order to avoid obscuring  
361 existing associations between different immune correlates.

#### 362 **Randomisation**

363 Since all samples that were available in South Australia were used in the study, no  
364 randomisation was performed in the experiments.

#### 365 **Blinding**

366 No experiments were blinded in this study.

### 367 **RESULTS**

#### 368 **Longitudinal SARS-CoV-2 humoral responses in mild-COVID-19 convalescents.**

369 The receptor binding domain (RBD) of SARS-CoV-2 Spike protein is the main target of  
370 neutralising antibodies (nAb), and nAb titers decline in the months after COVID-19 infection.  
371 Although not statistically significant, RBD-specific serum immunoglobulin had a downward  
372 trend for all isotypes between the time points analysed (figure 1B). The RBD IgG, IgG1 and  
373 IgG3 AUC titers decline was (95% CI, from 73.0-200.4 to 27.7-81.9), (from 66.8-218.2 to 0.8-  
374 3.8) and (from 0.0-44.3 to 0.18-0.92), respectively (figure 1B). In comparison with healthy  
375 seronegative control AUC values, RBD seropositivity for IgG isotypes was present in the  
376 majority of COVID-19 convalescents. This trend positively correlated with the presence of  
377 above background levels of circulating memory (CD27<sup>+</sup>) B cells expressing RBD-specific

378 surface IgG in 88.9% of individuals in the COVID-19 convalescent cohort (95% CI, 153-336  
379 cells/ 10<sup>6</sup> B cells) compared to healthy controls (95% CI, 0.0-27.9 cells/10<sup>6</sup> B cells) (figure 1C),  
380 indicative of the existence of long-term SARS-CoV-2-specific humoral immunity 12 months  
381 post-infection. Spike-specific IgG<sup>+</sup> B cells were also elevated in COVID-19 convalescents, but  
382 healthy control background frequencies were also higher (figure S2), likely due to cross-  
383 reactivity. RBD- and Spike-specific non-IgG<sup>+</sup> B cell frequencies were present a low rates (figure  
384 S2).

385 Obtaining long-term serum neutralisation data from communities free of circulating SARS-  
386 CoV-2, such as in this study, is difficult in other cohorts in the context of this pandemic. In our  
387 cohort, sera in 64% of convalescents at 12 months yielded ID<sub>50</sub> neutralisation titers  
388 significantly above healthy background levels against the pseudotyped virus bearing a  
389 Wuhan-like Spike protein, which is the same as the prevalent virus present in the community  
390 when study participants were infected (figure 1D).

391 Since early 2020, when the study participants were recruited, four VoC, namely, Alpha  
392 (B.1.1.7), Beta (B.1.351), Gamma (P1) and Delta (B.1.617.2), have dominated the landscape  
393 of COVID-19 outbreaks worldwide. Neutralisation titers against live-Wuhan virus were 16.8-  
394 40.8 (95% CI) with 51.2% of convalescents at 12 months presenting positive neutralising  
395 activity (figure 1E). Values were similar to those against pseudotyped virus particles bearing  
396 the same Spike protein sequence in figure 1D. As expected the percentage of patients with  
397 positive neutralising activity against B.1.1.7 virus did not differ significantly (44.2%) to Wuhan  
398 with titers ranging 12.8-29.9 (95% CI). However, a very significant drop in serum neutralisation  
399 titers was observed for live virus B.1351 (95% CI, 0.0-2.2), P.1 (0.2-9.9) and B.1.617.2 variants  
400 (1.1-10.9) with only 4.6%, 11.6% and 16.2% of convalescents, respectively, exhibiting positive  
401 neutralisation activity (figure 1E).

402 This is indicative that despite a high prevalence of RBD-seropositivity, existence of circulating  
403 memory B cells and homologous virus neutralisation activity among COVID19 convalescents,  
404 functional humoral responses to VoC are significantly reduced at 12 months post-infection.

#### 405 **Longitudinal quantification and phenotyping of SARS-CoV-2 T cell responses in mild-COVID-** 406 **19 convalescents.**

407 Along with antibody responses, the majority of COVID-19 convalescents develop SARS-CoV-2  
408 Spike- and non-Spike-specific T cell responses.<sup>48</sup> These T cells can be detected and quantified  
409 by means of activation-induced marker (AIM) assays using SARS-CoV-2 antigen peptide pools  
410 and flow cytometric analysis (figure S3).<sup>20,22,23</sup> For accurate interpretation in SARS-CoV-2 AIM  
411 assays, naïve healthy controls must be included in the analysis to establish assay baseline  
412 levels that arise from previous immunity to unrelated antigens/pathogens, and particularly to  
413 seasonal human coronaviruses.<sup>49</sup> In our cohort, the relative frequency of CD4<sup>+</sup> and CD8<sup>+</sup> T  
414 cells did not differ between the two time points (6 and 12 months) or between COVID-19  
415 convalescents and healthy controls (figure S4A).

416 AIM assays revealed that the frequency of circulating Spike-specific CD4<sup>+</sup> T cells did not  
417 significantly decrease between 6 and 12 months post-infection (95% CI, from 0.35-0.91 at 5-6  
418 months to 0.29-0.68) (figure 2A). The same trend was observed for non-Spike antigen CD4<sup>+</sup> T  
419 cells (from 0.22-0.43 to 0.18-0.37) and for the combined CD4<sup>+</sup> T cell response, Spike + non-  
420 Spike (from 0.60-1.33 to 0.49-1.04) (figure 2A).

421 Comparatively, the reduction of Spike-specific CD8<sup>+</sup> T cell frequency over time was more  
422 pronounced and statistically significant (95% CI, from 0.28-1.19 to 0.11-0.35,  $p < 0.01$ ) (figure  
423 3B). No statistically significant differences were observed for the frequencies of CD8<sup>+</sup> T cell  
424 reacting to whole SARS-CoV-2 proteome pools A and B (figure 2B). Convalescent AIM results  
425 were compared to naïve healthy controls in all instances, corroborating significantly lower T  
426 cell frequencies (baseline levels), consistent with previous AIM studies using the same peptide  
427 pools.<sup>22,23</sup> In addition, a positive control consisting of CMV protein peptides<sup>22,23,44</sup> was  
428 included for all healthy controls and 12 month convalescent data samples. As expected, a high  
429 percentage of individuals had a relatively high percentage of CMV-specific T cells (both CD4<sup>+</sup>  
430 and CD8<sup>+</sup>) with no significant differences between healthy and convalescent cohorts (figure  
431 S4B). These results are in line with other AIM longitudinal COVID-19 studies spanning from  
432 acute phase to up to 10 months after disease onset and indicate sustained maintenance of T  
433 cell responses one year post-infection.<sup>22,50</sup>

434 Next, we evaluated the memory phenotype of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells to  
435 support stronger conclusions on the specific roles of each population in the maintainance of  
436 SARS-CoV-2 immunity. Measuring the expression of surface markers CCR7 and CD45RA allows  
437 for the identification of different subsets of memory T cells, with different function, kinetics  
438 and frequency depending on the immune status, pathology and age.<sup>51</sup> In the AIM assay, we  
439 assessed the frequencies of SARS-CoV-2-specific T cells within the total pool of central  
440 memory (T<sub>CM</sub>, CCR7<sup>+</sup>CD45RA<sup>-</sup>) T cells, effector memory T cells (T<sub>EM</sub>, CCR7<sup>-</sup>CD45RA<sup>-</sup>), terminally  
441 differentiated or terminal effector T cells (T<sub>EMRA</sub>, CCR7<sup>-</sup>CD45RA<sup>+</sup>) and naïve T cells (T<sub>N</sub>,  
442 CCR7<sup>+</sup>CD45RA<sup>+</sup>) in both CD4<sup>+</sup> and CD8<sup>+</sup> T pools. Between 6 and 12 months post infection, the  
443 frequency of Spike-specific CD4<sup>+</sup> T cells were significantly reduced in all three memory  
444 compartments, T<sub>CM</sub> (95% CI, from 0.32-0.73 to 0.17-0.37,  $p < 0.05$ ), T<sub>EM</sub> (1.2-2.4, 0.75-1.52,  
445  $p < 0.05$ ) and T<sub>EMRA</sub> (0.67-1.20, 0.29-0.85,  $p < 0.01$ ) (figure 3A). Although the trend is similar for  
446 non-Spike CD4<sup>+</sup> T cell memory subsets, the differences between time points were not  
447 statistically significant (figure 4A). The combined data (Spike + non-Spike CD4<sup>+</sup> T cell subsets)  
448 showed statistically significant decrease in SARS-CoV-2-specific CD4<sup>+</sup> T<sub>CM</sub> (0.51-1.06, 0.28-  
449 0.60,  $p < 0.05$ ), T<sub>EM</sub> (2.11-3.68, 1.22-2.24,  $p < 0.05$ ) and T<sub>EMRA</sub> (0.98-1.83, 0.58-1.37,  $p < 0.01$ )  
450 (figure 3A). Importantly, effector memory T cell (T<sub>EM</sub>) phenotype was clearly predominant in  
451 SARS-CoV-2-specific CD4<sup>+</sup> T cells making up >60% and >50% of all CD4<sup>+</sup>OX40<sup>+</sup>CD137<sup>+</sup>, at 6 and  
452 12 months respectively, irrespective of antigen specificity (figure 3B).

453 Analysis of the SARS-CoV-2-specific memory CD8<sup>+</sup> T cells revealed important differences,  
454 compared to CD4<sup>+</sup> T cells. Predominant CD8<sup>+</sup> T<sub>EMRA</sub> cells specific to SARS-CoV-2 suffered a  
455 pronounced reduction regardless of antigen specificity. The frequency of Spike-specific CD8<sup>+</sup>

456 T<sub>EMRA</sub> decreased from 0.66-1.96 to 0.23-0.70 (95% CI, p<0.001), as well as for the for SARS-  
457 CoV-2 whole proteome, (from 0.38-0.92 to 0.07-0.38, p<0.001, for pool A) (from 0.12-1.18, to  
458 0.02-0.34, p<0.001, for pool B) (figure 4A). The importance of T<sub>EMRA</sub> cells within the CD8<sup>+</sup> T  
459 pool in COVID-19 convalescents was further highlighted as they were the predominant  
460 proportion of CD8<sup>+</sup>CD69<sup>+</sup>CD137<sup>+</sup> cells at 6 months (>65%) and at 12 months (>60%),  
461 irrespective of antigen specificity (figure 4B).

462 The presence of significant frequencies of SARS-CoV-2 antigen-specific CD4<sup>+</sup> T<sub>EM</sub> and CD8<sup>+</sup>  
463 T<sub>EMRA</sub> at 12 months, has important implications, particularly in the absence of virus re-  
464 exposure, given that in principle these cells have a limited life-span. Importantly, a significant  
465 decrease in these populations from 6 to 12 months suggests that in the absence of  
466 restimulation by either infection or vaccination, these populations will eventually not be  
467 detectable in circulation, or plateau at low frequencies for extended periods of time. In future,  
468 the renewal mechanisms of both of these cell populations is an important question that needs  
469 to be addressed.

#### 470 **Functionality of Spike-specific T cells in ‘high-responder’ convalescents.**

471 A direct indicator of T cell effector function is their ability to produce immunomodulatory  
472 cytokines upon antigen stimulation. Since Spike was the immunodominant SARS-CoV-2  
473 antigen according to our AIM results (figure 2), we selected COVID-19 convalescents with  
474 Spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses well above healthy control levels (mean plus  
475 3\*standard deviations) (figure 5A), hereafter referred to as ‘**high responders**’. We performed  
476 a Spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell intracellular cytokine staining (ICS) assay measuring the  
477 pleiotropic signalling cytokines interferon gamma (IFN $\gamma$ ) and tumor necrosis factor alpha  
478 (TNF $\alpha$ ), as well as the cytotoxic enzymes, granzyme B (GZMB) and perforin (PRF1), and T cell-  
479 activation factor, interleukin-2 (IL-2). Additionally, we evaluated the frequency and  
480 functionality of Spike-specific circulating T follicular helper cells (cT<sub>FH</sub>) given their importance  
481 for immune memory in COVID-19 convalescents<sup>22,52</sup> (see figures S5 and S6 for ICS/cT<sub>FH</sub> gating  
482 strategy).

483 At 12 months post-infection, the frequency (%) of Spike-specific cT<sub>FH</sub> cells in COVID-19  
484 convalescents was not significantly different (95% CI, 1.48-0.21) to that of healthy controls  
485 (0.27-0.05) (figure 5B). The frequency of IFN $\gamma$ <sup>+</sup> (figure 5B), TNF $\alpha$ , GZMB, PRF1 or IL-2 (figure  
486 S7) positive cT<sub>FH</sub> cells also did not differ from that of healthy controls. This is, to our  
487 knowledge, the first report of cytokine expression data in cT<sub>FH</sub> in COVID-19 convalescents at  
488 12 months post infection.

489 The reactivity of CD4<sup>+</sup> T cells in high-responder convalescents to the whole Spike protein was  
490 dominated by a higher percentage of CD4<sup>+</sup> T cells expressing IFN $\gamma$  (95% CI, 0.26-0.02, p<0.001)  
491 and TNF $\alpha$  (0.16-0.02, p<0.01) (figure 5C). The percentage of CD4<sup>+</sup> T cells expressing GZMB,  
492 PRF1 and IL-2 were not significantly higher than in healthy controls (figure 5C). In agreement  
493 with their known cytotoxic function, Spike-specific CD8<sup>+</sup> T cells in COVID-19 convalescents  
494 exhibited high frequencies of GZMB (95% CI, 12.30-1.43, p<0.01) and PRF1 (11.27-2.56,

495 p<0.001) while IFN $\gamma$ , TNF $\alpha$  or IL-2 expressing cells were not significantly different (figure 5D).  
496 Taken together, our AIM and ICS data clearly show a durable, multifunctional response of  
497 circulating helper and cytotoxic T cells 12 months post-COVID-19 infection. Importantly, we  
498 show that cT<sub>FH</sub> frequencies and their effector function were diminished.

#### 499 **T cell specificity to VoC Spike mutated sequences in mild-COVID-19 ‘high responders’.**

500 Recent studies suggest that T cell specificity to whole Spike antigen and other SARS-CoV-2  
501 proteins is relatively unaffected by the changes in Spike amino acid sequence characteristic  
502 of current VoC.<sup>25</sup> However, these studies have either used peptide pools covering both  
503 mutated and non-mutated regions of individual antigens (Spike and non-Spike),<sup>25</sup> in which  
504 mutated peptides represent a very small proportion of the overall pool. Hence any differences  
505 in T cell specificities and functionality against the mutations in the Spike antigen of VoC were  
506 potentially masked. Others, used mutation-specific Spike peptides, but only for B.1.1.7 and  
507 B.1.351 VoC.<sup>26</sup> Here, we have tested T cell specificity and functionality to the Spike protein of  
508 all four VoC with peptide pools covering corresponding mutated regions by intracellular  
509 cytokine staining in ‘high-responder’ COVID19 convalescents (n=15) matching reagents and  
510 analysis strategies (figures S7 and S8) from previous studies to allow for relevant  
511 comparisons.<sup>25,26</sup>

512 For the context of this experiment and its results, it is important to note that our cohort was  
513 infected in early 2020 in Australia, where SARS-CoV-2 with unmutated Spike amino acid  
514 sequences was prevalent (figure 6A). In order to clearly identify any changes in functionality  
515 of T cell immunity to the Spike antigen present in the current VoC, we set a 2-fold decrease  
516 (50%), as a threshold to compare the T cell reactivity to mutated Spike peptide pools with that  
517 to reference (unmutated) Spike pools (denoted by a red dotted line in figures 6B and 6C). We  
518 show that CD4<sup>+</sup> T cell cytokine responses were significantly more affected by mutations in  
519 VoC Spike antigens, compared to CD8<sup>+</sup> T cell cytokines responses (figures 6B and 6C). There  
520 were 56 instances where a convalescent showed >2-fold reduction for one of the cytokines  
521 for one VoC for CD4<sup>+</sup> T cells compared to 14 for CD8<sup>+</sup> T cells. Mutations present in the Spike  
522 antigen of B.1351 variant induced the highest number of >2-fold reductions in CD4<sup>+</sup> T cell  
523 cytokine/VoC responses in the ‘high responder’ cohort with 23 (41%) of the all (56) of such  
524 reductions followed by B.1.617.2 (15, 26%) (figure 6B). These reductions occurred at higher  
525 frequency for IFN $\gamma$  responses in CD4<sup>+</sup> T cells (16) compared to TNF $\alpha$ , GZMB, PRF1 or IL-2 (12,  
526 10, 11 and 7, respectively) (figure 6B). Only IFN $\gamma$  production was significantly affected in CD8<sup>+</sup>  
527 T cells, with (9 reductions) and no obvious differences in terms of VoC driving these  
528 differences (figure 6C).

529 Strikingly, when the same data was analysed looking at individual COVID-19 convalescent  
530 participants, 86% of ‘high responders’ exhibited at least one deficient T cell cytokine response  
531 (>2-fold) for one of the VoC (table S2). In these convalescents, 48% of all cytokine T cell  
532 deficient responses occurred in 4 out of 15 convalescents, clearly indicating differences in the  
533 vulnerability to VoC of different convalescents even within a group of ‘high responders’ (table

534 S2). To our knowledge, this is the first time that a loss of Spike-specific T cell functionality  
535 against VoC, despite durable (12 months) maintenance in overall frequency, has been  
536 reported in COVID-19 convalescents. These data suggest that suboptimal Spike-specific T  
537 helper cell functional responses are more likely to occur in convalescents (infected with  
538 Wuhan-like variants) who encounter B.1.351 or B.1.617.2, rather than other VoC. This is  
539 similar to what happens with humoral antibody responses in COVID-19 convalescents and  
540 vaccinees,<sup>12,16,18</sup> and is further supported by our live-virus neutralisation data (figure 1E).

## 541 **Discussion.**

542 The evidence from large observational studies in healthcare workers and the general  
543 population suggests that SARS-CoV-2 immunity post infection confers a level of protection  
544 against COVID-19.<sup>53-55</sup> One caveat of these studies is that high rates of transmission of SARS-  
545 CoV-2 in the communities where the studies were conducted (*e.g.* Italy, UK or USA) increased  
546 the likelihood of virus re-exposure in that cohort, precluding the ability to draw firm  
547 conclusions on the duration and protective effects of primary SARS-CoV-2 immunity.

548 Controlled, in-depth studies in convalescents have also been conducted, but vaccination and  
549 almost ubiquitous high SARS-CoV-2 infection rates have reduced the opportunities to recruit  
550 convalescents long after COVID-19 disease, and importantly, in the absence of re-infection.

551 Conversely, vaccination programs allow for more controlled studies and deeper immune  
552 analysis and facilitate conducting experimental procedures to test immune fitness against  
553 VoC. However, to date, the majority of vaccinees have received Spike-based vaccines, which  
554 are not well-suited as a proxy for what SARS-CoV-2 immunity may look like in the long-term,  
555 or its adaptability to VoC. Here, we have taken advantage of the relatively unique situation in  
556 South Australia, where local transmission of SARS-CoV-2 was eliminated early on in the  
557 pandemic in 2020, enabling us to conduct a 12-month longitudinal study of SARS-CoV-2  
558 immunity in mild-COVID-19 convalescents and test their immune fitness against the current  
559 VoC.

560 Total RBD IgG titers and other circulating Ig isotypes against SARS-CoV-2 Spike and RBD  
561 antigens decrease over the months following COVID-19 disease, with the strongest decline in  
562 the first 1-3 months.<sup>22,36,56</sup> A concordant trend was also observed in our cohort between 6  
563 and 12 months. A recent study in Wuhan (China), where RBD-specific IgG was longitudinally  
564 assessed in convalescents up to 12 months post-COVID-19 in a community with absence of  
565 SARS-CoV-2 local transmission, analogous to that of South Australia, showed a similar trend  
566 between 6 and 12 months.<sup>9</sup> It is worth noting that the genome sequence of the virus variants  
567 causing COVID-19 in each of the studies are closely related and in the absence of VoC. Despite  
568 declining circulating antibody titers, the majority of convalescents in our cohort (>90%) had  
569 significantly higher levels of Spike- and RBD-specific total IgG compared to the healthy  
570 controls at 12 months post-COVID-19. Concomitantly, circulating RBD-specific memory B cells  
571 were present in 88.9% of convalescents, indicating that antibody responses could extend  
572 further into the future.

573 The presence of specific antibodies alone does not necessarily predict protection against  
574 disease. Mathematical modelling of clinical data indicates that a minimum specific Ig titer is  
575 needed for protection against COVID-19 disease.<sup>57</sup> This is also supported by clear evidence  
576 showing that serum virus neutralisation activity, exerted by a portion, but not all antibodies,  
577 is the best predictor of protection.<sup>48,55,57,58</sup> Both live-virus and pseudovirus serum  
578 neutralisation assays indicated that sera from 51% and 65%, respectively, of COVID19  
579 convalescents can efficiently neutralise SARS-CoV-2 bearing the Spike protein homologous to  
580 one which caused the original infection, 12 months post-infection. At 6-8 months post-COVID-  
581 19, the percentage of convalescents who retain serum neutralizing activity, estimated with  
582 methods similar or identical to ours, varies considerably, from ~60% to >90%.<sup>8,22,36,43</sup> It is  
583 important to note that these studies included more heterogenous cohorts, which included  
584 severe COVID-19 patients. Overall, virus neutralisation measures in our cohort (51-65%) 12  
585 months post-infection are in line with previous findings.

586 Recent modelling data predicted the risk of reinfection in COVID19 convalescents to emerging  
587 variants of SARS-CoV-2 and showed that reinfection likelihood is high, at median time of 16  
588 months after primary infection, earlier than for other human coronaviruses.<sup>59</sup> Empirical data  
589 is needed to confirm these predictions to better manage the ongoing pandemic.

590 We demonstrated with live-virus neutralisation data that despite the maintenance of serum  
591 antibodies at 12 months post infection in 90% of mild COVID-19 convalescents, they have  
592 significantly decreased ability to neutralise the four main VoC. It is striking to see that serum  
593 neutralising activity against B.1.351 is practically non-existent, and for both P.1 and the  
594 pervasive variant B.1.617.2, the drop in the number of patients who retain serum  
595 neutralisation activity is >65%. For B.1.1.7, the first VoC (chronologically), and perhaps less  
596 relevant at the present time, the reduction in neutralisation titers was less pronounced. The  
597 relative differences at 12 months post-infection between the VoC correlated well with other  
598 COVID-19 convalescent and vaccination studies.<sup>13,14,16,18,57,60-62</sup> Our measurements at 12  
599 months post-COVID-19 and in the absence of re-infection, reveal that although circulating  
600 SARS-CoV-2 antibody responses persist up to 12 months, the antigenic drift of SARS-CoV-2 in  
601 VoC outperforms humoral immune responses in mild-COVID-19 convalescents.

602 As such, our findings stress the necessity to reinforce the immune system to overcome these  
603 insufficiencies in COVID-19 convalescents via vaccination.

604 Importantly, we report that SARS-CoV-2-specific circulating CD4<sup>+</sup> and CD8<sup>+</sup> T cell frequencies  
605 are maintained in a significant proportion of convalescents between 6 and 12 months post-  
606 COVID-19 and at levels reported for earlier time points,<sup>22,23</sup> indicating that these T cell  
607 populations are stable. While >50% of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were  
608 directed at the Spike protein, a significant proportion of T helper and cytotoxic T cells were  
609 activated by non-Spike antigen epitopes.

610 Collectively, memory compartment analysis of circulating SARS-CoV-2-specific T cells strongly  
611 suggests that in mild-COVID-19 convalescents, CD4<sup>+</sup> T<sub>EM</sub> and CD8<sup>+</sup> T<sub>EMRA</sub> have significant roles

612 in maintaining immunity as far as 12 months after infection. Interestingly, the maintenance  
613 and large proportion of CD8<sup>+</sup> T<sub>EMRA</sub> bears resemblance to the -kinetics of equivalent cells in  
614 long-term chronic infections by human CMV.<sup>63</sup> A significant decay of Spike-specific CD4<sup>+</sup> T<sub>CM</sub>  
615 cells was observed, however this was not reflected in their CD8<sup>+</sup> T cell counterparts, perhaps  
616 indicating that in the long term, cytotoxic immune function could be sustained more  
617 efficiently thanks to cell self-renewal and proliferation.<sup>51</sup> Importantly, in our cohort of ‘high  
618 responders’, T cells showed a strong capacity to produce a range of cytokines, with strong  
619 IFN $\gamma$  and TNF $\alpha$  responses in CD4<sup>+</sup> T cells and GZMB and PRF1 in CD8<sup>+</sup> T cells, in concordance  
620 with their respective helper and cytotoxic function profiles.

621 At 12 months post-infection we did not detect significant frequencies of circulating Spike-  
622 specific cT<sub>FH</sub> cells, even in ‘high-responder’ convalescents, which is in agreement with studies  
623 that showed their decline in earlier months after infection<sup>22</sup> and vaccination.<sup>64</sup>

624 The current understanding of SARS-CoV-2 infection-induced T cell responses with respect to  
625 their ability to adapt to VoC with Spike antigen mutations, is that contrary to antibody  
626 responses, T cells significantly maintain reactivity to such mutated antigens.<sup>25,26</sup> In contrast,  
627 we show, with a functional cytokine T cell assay, that changes in the Spike amino acid  
628 sequence corresponding to VoC, led to functional vulnerabilities, where even ‘high responder’  
629 COVID-19 convalescents exhibited reduced cytokine production in response to mutated Spike  
630 antigen epitopes. Importantly, we found that a subset of ‘high responder convalescents’  
631 accumulated most of these functional deficiencies in their CD4<sup>+</sup> T cell compartment, rather  
632 than cytotoxic CD8<sup>+</sup> T cells, with such deficiencies more pronounced against B.1.351 Spike  
633 epitopes.

634 The ability of viruses to escape virus-specific T cell responses is known.<sup>65,66</sup> In fact, viruses  
635 such as influenza can escape T cell responses after acquiring single amino acid mutations.<sup>67</sup>  
636 Hepatitis C virus is also capable of escaping T cell responses with minimal variations to antigen  
637 amino acid sequences.<sup>68</sup> Our findings are concerning, since additional mutations leading to  
638 the appearance of new SARS-CoV-2 variants could potentially increase the ability of the virus  
639 to escape pre-existing Spike-specific T cell responses.

640 Our results regarding T cell adaptability to VoC are limited in that we have only tested cytokine  
641 responses to a single antigen, Spike. Our AIM assay results clearly show that Spike is the main  
642 driver of immune responses in convalescents, but immunity to other non-Spike proteins is  
643 also important. Variation in direct T cell effector function (cytokine production) to  
644 corresponding non-Spike antigenic VoC sequences was not tested and, therefore, the  
645 combined SARS-CoV-2 protein effect of VoC mutations on T cell immune function is yet to be  
646 fully elucidated. Prior to this study, Tarke *et al* conducted multiantigenic studies (including,  
647 Spike, N, M, and a range of ORFs and NSPs) to test T cell responses to VoC (excluding the  
648 prevailing B.1.617.2 variant), concluding that T cell reactivity to ancestral Wuhan antigen  
649 epitopes and virus variants was not significantly different. In their experimental design, they  
650 used an AIM assay-based approach with large peptide pools, which included mutated and

651 non-mutated epitopes. While this approach bears more resemblance to what might happen  
652 during a SARS-CoV-2 infection, it potentially masks subtle differences in T cell reactivity and  
653 the identification of individuals whose T cell responses are more severely affected by  
654 antigenic changes in the Spike antigen of VoC.<sup>25</sup> Also, while the AIM assay is a powerful  
655 method to detect and quantify T cell antigen specificity it does not measure function directly,  
656 compared to ICS.

657 On the other hand, while testing Spike alone may be a limitation when assessing convalescent  
658 responses, our results have important implications in assessing immunity elicited by most of  
659 the current vaccines administered in developed countries, which are based, exclusively, on  
660 the Wuhan- Spike protein (e.g., vaccines produced by AstraZeneca, Pfizer-BioNTech, Janssen  
661 or Moderna). If the deficiencies reported here have an equivalent in uninfected vaccinees,  
662 then, functional T cell responses could be compromised in these individuals. Future studies  
663 must address this question.

664 In summary, our findings reveal that, despite the durability and maintenance of serum  
665 antibodies, circulating memory B cells and T cell responses at 12 months after original  
666 infection, COVID-19 convalescents have pronounced deficiencies in functional Spike-specific  
667 T cell responses and the ability to neutralise the current VoC. As such, mild-COVID-19  
668 convalescents are vulnerable to infection with circulating and newly emerging SARS-CoV-2  
669 variants 12 months after recovery. The results obtained from our functional evaluation of  
670 post-COVID-19 immunity are in line with current large observational studies, that  
671 demonstrate the added protective effect of COVID-19 vaccines in previously infected  
672 individuals.<sup>69,70</sup> Thus our study highlights the importance and necessity to vaccinate COVID19  
673 convalescents against subsequent SARS-CoV-2 infections.

674 Finally, it is important to consider our findings in the context of the existing worldwide  
675 inequalities in vaccine distribution, which have kept many developing countries from Africa,  
676 South East and South Central Asia and Central America at vaccination rates <20% so far.<sup>71</sup>  
677 These regions are, therefore, more vulnerable to outbreaks of emerging SARS-CoV-2 variants  
678 with the ability to evade pre-existing immune responses in unvaccinated convalescents.<sup>72,73</sup>

679

#### 680 **Author contributions**

681 Writing original manuscript draft: PGV, BGB and MGM. Editing manuscript: SCB, MRB, CKL,  
682 EJJ, GM and DJL. Design of experiments: PGV, CMH, MGM, AS, DW, SGT, BGB, SCB and RAB.  
683 Performed experiments: PGV, CMH, MGM, AELY, HB, ZAM, ZAD, AA, AOS, AA and DA. Data  
684 analysis: PGV, CMH, AELY, BGB, RAB. Patient sample collection: CMH, JG, CF, SO, EMM, BAJR,  
685 DS, and CKL. All authors reviewed, discussed, and agreed with manuscript.


#### 686 **Declaration of competing interests**

687 AS is currently a consultant for Gritstone, Flow Pharma, Arcturus, Epitogenesis,  
688 Oxfordimmunotech, Caprion and Avalia. La Jolla Institute for Immunology (AS and DW) has  
689 filed for patent protection for various aspects of T cell epitope and vaccine design  
690 work. Authors PGV, CMH, MGM, AELY, HB, ZAM, ZAD, AA, DA, AOS, AA, JG, CF, SO, EMM, DJL,  
691 GM, EJG, BAJR, DS, CKL, SGT, MRB, DW, RAB, SCB and BGB declare no conflict of interest.

## 692 **Acknowledgements**

693 This work was funded by project grants from The Hospital Research Foundation and Women's  
694 and Children's Hospital Foundation, Adelaide, Australia. MGM is THRF Early Career Fellow.  
695 BGB is THRF Mid-Career Fellow. This work has been supported by NIH contract  
696 75N9301900065 (A.S, D.W). We would like to thank Ms. Suzanne Edwards, University of  
697 Adelaide, for statistical advice and analysis.

698 **FIGURES**



699

700

701 **Figure 1. Circulating RBD-specific antibodies, memory B cells frequency and serum SARS-CoV-2**  
702 **neutralisation activity at 12 months after PCR positive test.**

703 (A) Forty-three SARS-CoV-2 infected individuals who presented mild-COVID-19 symptoms were  
704 recruited after a PCR positive test and serum and PBMCs were sampled at 6 and 12 months.


705 (B) Serum RBD- specific antibody titers, per Ig isotype, reported as area under the curve (AUC) units.  
706 Circles represent AUC individual patient values (n=43 at 6 months, orange, and 12 months, yellow,  
707 n=15 for healthy controls, blue), with mean value denoted by a horizontal black line. Seronegative  
708 samples were assigned a value of 0.001 data visualisation purposes.

709 (C) SARS-CoV-2 RBD-specific (n=28) memory B cells (CD27<sup>+</sup>) were quantified 12 month post-infectioin  
710 with corresponding specific tetramers and further characterised as IgG<sup>+</sup>. Cell population-specific  
711 background was calculated with healthy control PBMCs and shown as a red dashed line.<sup>36</sup>

712 (D) Serum neutralisation ID<sub>50</sub> of SARS-CoV-2, MLV pseudovirus particles expressing infectious  
713 homologous Spike sequence (Wuhan) in mild-COVID-19 convalescent sera (n=42) at 12 months after  
714 positive COVID-19 test. Positive neutralization percentage (indicated above figure) activity cut-off (ID<sub>50</sub>  
715 = 22.61) was calculated from 19 healthy control samples, shown as a red dashed line.

716 (E) Patient serum neutralisation end-point cut-off titers (highest dilution factor that yields ≥50%  
717 inhibition of cell death after live virus infection) at 12 months against Wuhan, B.1.1.7, B.1.351, P.1 and  
718 B.1.617.2 live virus particles. Forty was the initial dilution for all serum samples. Neutralisation activity  
719 was considered negative, value of zero, when neutralisation of initial serum dilution was <50%. \*, \*\*,  
720 \*\*\*, and \*\*\*\* denote P values < 0.05, 0.01, 0.001, 0.0001 respectively. ns = not significant.

721




722

723 **Figure 2. SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell frequencies in mild-COVID-19 convalescents at 6**  
 724 **and 12 months after PCR positive test.**

725 (A) Percentage of activated CD4<sup>+</sup> T cells (OX40<sup>+</sup>CD137<sup>+</sup>) after stimulation with Spike, non-Spike and  
 726 cumulative (Spike + non-Spike) antigen peptide pools within the total CD3<sup>+</sup>CD4<sup>+</sup> T cell population of  
 727 PBMCs in individual mild-COVID-19 patients (n=43) at 6 and 12 months after COVID-19 positive test  
 728 (orange and yellow) and healthy controls (n=15, in blue). (B) Percentage of activated CD8<sup>+</sup> T cells  
 729 (CD69<sup>+</sup>CD137<sup>+</sup>) after stimulation with Spike, whole proteome, A and B antigen peptide pools within  
 730 the total CD3<sup>+</sup>CD8<sup>+</sup> T cell population of PBMCs in same samples as in (A). Dots in a represent patient  
 731 or healthy control individual values. Averages are denoted by a horizontal line and statistically  
 732 significant differences between patient and healthy controls indicated by asterisks. \*, \*\*, \*\*\* and \*\*\*\*  
 733 denote *P* values < 0.05, 0.01, 0.001 and 0.0001, respectively. ns = not significant.

734




735

736 **Figure 3. Memory immunophenotyping and quantification of SARS-CoV-2-specific  $CD4^+$  T cells in**  
 737 **mild-COVID-19 convalescents at 6 and 12 months after PCR positive test.**

738 (A) Memory immunophenotype based on expression of surface CCR7 and CD45RA of SARS-CoV-2  
739 Spike-, non-Spike- and cumulative (Spike + non-Spike)-specific CD4<sup>+</sup> T cells detected in Figure 2A. Cells  
740 were classified as follows: naïve (T<sub>N</sub>, CCR7<sup>+</sup>CD45RA<sup>+</sup>), central memory (T<sub>CM</sub>, CCR7<sup>+</sup>CD45RA<sup>-</sup>), effector  
741 memory (T<sub>EM</sub>, CCR7<sup>-</sup>CD45RA<sup>-</sup>) and terminally differentiated effector memory cells re-expressing  
742 CD45RA (T<sub>EMRA</sub>, CCR7<sup>-</sup>CD45RA<sup>+</sup>). Frequencies are indicated as percentage of total SARS-CoV-2 antigen-  
743 specific CD4<sup>+</sup> T cells within the total pool of immune cells with same phenotype in the patient's PBMCs.  
744 (B) Doughnut charts indicating the proportion (%) of each immune phenotype in (A) of the total of  
745 SARS-CoV-2-specific CD4<sup>+</sup> T cells for each antigen. In (A) circles represent patient individual values.  
746 Averages are denoted by a horizontal line and statistically significant differences between time points  
747 indicated by asterisks. \* and \*\* denote *P* values < 0.05 and 0.01, respectively. ns = not significant.


748



749

750 **Figure 4. Memory immunophenotyping and quantification of SARS-CoV-2-specific CD8<sup>+</sup> T cells in**  
 751 **mild-COVID-19 convalescents at 6 and 12 months after PCR positive test.**

752 (A) Memory immunophenotype based on expression of surface CCR7 and CD45RA of SARS-CoV-2  
753 Spike-, whole proteome pools A- and B-specific CD8<sup>+</sup> T cells detected in Figure 2B. Immune phenotypes  
754 were defined as in Figure 3. Frequencies are indicated as percentage of total SARS-CoV-2 antigen-  
755 specific CD8<sup>+</sup> T cells within the total pool of immune cells with same phenotype in the patient's PBMCs.  
756 (B) Doughnut charts indicating the proportion (%) of each immune phenotype in (A) of the total of  
757 SARS-CoV-2-specific CD8<sup>+</sup> T cells for each antigen. In (A) circles represent patient individual values.  
758 Averages are denoted by a horizontal line and statistically significant differences between time points  
759 indicated by asterisks. \*\*\* and \*\*\*\* denote *P* values < 0.05 and 0.01, respectively. ns = not significant.  
760




761

762 **Figure 5. Cytokine expression and circulating T follicular helper cell frequencies in convalescents**  
763 **with strong T cell immune responses to SARS-CoV-2 Spike protein.**

764 (A) Fifteen Spike “high responder” convalescents were selected based on the criterion of >healthy  
765 control average +3SD of Spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell frequencies in the AIM assay (Figure 2)  
766 and further analysed for Spike-specific cT<sub>FH</sub> and ICS analysis using the whole Spike peptide pool.

767 (B) Frequency of circulating Spike-specific T follicular helper cells (CD4<sup>+</sup>CXCR5<sup>+</sup>iCD154<sup>+</sup>) in healthy  
768 controls (n=15) and selected high responder convalescents (n=15) and % of IFN $\gamma$ <sup>+</sup> cells.  
769 (C) Percentage of cytokine positive expression in CD3<sup>+</sup>CD4<sup>+</sup>iCD154<sup>+</sup> T cells in same individuals as (B).  
770 (D) Percentage of cytokine positive expression in CD3<sup>+</sup>CD8<sup>+</sup> T cells in same individuals as (B). In B, C  
771 and D circles represent healthy or patient individual values. Averages are denoted by a horizontal line  
772 and statistically significant differences between time points indicated by asterisks. \*\* and \*\*\* denote  
773 *P* values < 0.01 and 0.001, respectively. ns = not significant.  
774  
775

776



777

778 **Figure 6. Specific T cell responses in responder convalescents to mutated Spike amino acid**  
 779 **sequences in VOCs.**

780 (A) PBMCs from spike responders (n=15, same as in figure 5) were stimulated with peptides covering  
 781 mutated Spike regions in VoCs and cytokine expression was measured by intracellular cytokine  
 782 staining (ICS).

783 (B) Fold-change cytokine expression in CD3<sup>+</sup>CD4<sup>+</sup>iCD154<sup>+</sup> T cells. Negative Folds denote decrease in  
 784 cytokine expression when stimulated with mutated peptide pools. Red dotted line indicates a 2-fold  
 785 decrease in cytokine expression with corresponding mutated peptide pool.

786 (C) Fold-change cytokine expression in CD3<sup>+</sup>CD8<sup>+</sup> T cells. Negative Folds denote decrease in cytokine  
 787 expression when stimulated with mutated peptide pools. Red dotted line indicates a 2-fold  
 788 decrease in cytokine expression with corresponding mutated peptide pool. \* and \*\* denote P values < 0.05 and  
 789 0.01, respectively. Non statistically significant differences were not indicated for clarity.

790

791

792

793

794

795

## Supplementary Information

796 **Table S1. PepTivator® peptide pool mutation and deletions.**

<b>Variant</b>	<b>WHO name</b>	<b>Mutations and deletions</b>
B.1.1.7	Alpha	del 69, del 70, del 144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H.
B.1.351	Beta	D80A, D215G, del 242, del 243, del 244, K417N, E484K, N501Y, D614G, A701V
P.1	Gamma	L18, T20, P26, D138, R190, K417, E484, N501, D614, H655, T1027, V1176
B.1.617.2	Delta	T19, G142, E156, F157, R158, L452, T478, D614, P681, D950

797


798

799 **Table S2. No. of times each high-responder convalescent exhibited cytokine T cell frequencies**  
800 **reduced by >2-fold when stimulated with any of the mutated VoC Spike peptide pools in figure 6.**

ID	CD4+ cytokine	CD8+ cytokine	total
15-006	5	0	5
15-008	11	0	11
15-012	6	3	9
15-013	2	0	2
15-016	4	1	5
15-020	5	1	6
15-030	2	2	4
15-046	4	0	4
15-054	4	2	6
15-056	0	0	0
15-058	5	2	7
15-059	4	3	7
15-062	0	0	0
15-065	1	0	1
15-070	3	0	3

801


802



803

804 **Figure S1. Age and gender distribution of COVID-19 convalescents and healthy control subjects**  
805 **recruited for this study.**

806




807

808 **Figure S2. Spike and RBD-specific memory B cells in COVID-19 convalescents.**

809 The number of Spike and RBD-specific IgG<sup>+</sup>, IgD<sup>+</sup> or IgG<sup>-</sup>IgD<sup>+</sup> memory (CD27<sup>+</sup>) B cells per million B cells  
810 in COVID-19 convalescents at 12 months post disease onset was evaluated by tetramer staining. Data  
811 represented as 5-95 percentile box plots and standard deviation error bars. Staining average + 2\*  
812 standard deviation values obtained in healthy (uninfected) controls are denoted by dashed red lines  
813 in each case.


814



815

816 **Figure S3. AIM assay gating strategy.**

817 Live, CD14<sup>-</sup>CD19<sup>-</sup>CD3<sup>+</sup> singlets were gated and further classified as either CD4<sup>+</sup> or CD8<sup>+</sup> T cells  
 818 using gating strategy on two top row panels. Antigen specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were  
 819 identified based on double expression of surface CD137 and OX40 or CD137 and CD69,  
 820 respectively (lower panels). Finally, memory phenotype of antigen-specific cells was further  
 821 determined according to expression of surface CCR7 and CD45RO.



822

823 **Figure S4. T lymphocytes and CMV-specific CD4<sup>+</sup> and CD8<sup>+</sup> cells in study participants.**

824 (A) Left to right, percentage of CD3<sup>+</sup>, CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cells in COVID-19 convalescents at 6  
 825 and 12 months after disease onset (n=43) and healthy controls (n=15) analysed in the AIM assay. (B)  
 826 CD4<sup>+</sup> and CD8<sup>+</sup> CMV-specific T cells in healthy controls and COVID-19 convalescents at 12 months after  
 827 SARS-CoV-2 infection. \*\*\*\* and ns denote statistically significantly differences at p < 0.0001 and not  
 828 significant, respectively.


829

830

831

832

833




834

835 **Figure S5. Flow cytometry data gating strategy for whole Spike (Wuhan)-specific intracellular**  
836 **cytokine (ICS) assay and activated T Follicular Helpers.**

837 Representative strategy to define CD4, CD8 and T Follicular helpers (CD4+ CXCR5+) for the  
838 intracellular cytokine assay and activation induced CD154 (CD40L) expression. CD154 was measured  
839 for activation of T Follicular helpers.


840



841

842 **Figure S6. Whole (Wuhan) Spike-specific ICS assay gating strategy.**

843 Flow cytometry data gating strategy for Wuhan spike-specific intracellular cytokine (ICS) assay  
 844 Representative strategy to measure Wuhan-spike-specific (A) CD4, (B) CD4 Tfh and (C) CD8 T cells via  
 845 percentage of intracellular cytokines: perforin (PRF1), Tumour Necrosis Factor alpha (TNFα),  
 846 Granzyme B (GZMB), IL-2 and Interferon gamma (IFN-γ). PBMC were stimulated with Wuhan spike  
 847 megapool.  
 848




849

850 **Figure S7. Cytokine expression in Spike-specific T follicular helper cells.**

851 Intracellular cytokine expression in circulating T follicular helper cells (CXCR5+CD154+CD4+) in healthy  
852 controls (n=15) and COVID-19 convalescents at 12 months after infection (n=15). ns denotes not  
853 statistically significant.

854



856 **Figure S8. Flow cytometry data gating strategy for Variants of Concern (VoC)-spike-specific**  
 857 **intracellular cytokine (ICS) assay for CD4 T cells.**

858 Representative strategy to measure Variants of Concern (VoC)-spike-specific CD4 T cells via  
 859 percentage of intracellular cytokines: perforin (PRF1), Tumour Necrosis Factor alpha (TNF $\alpha$ ),  
 860 Granzyme B (GZMB), IL-2 and Interferon gamma (IFN- $\gamma$ ). PBMC were stimulated with either VoC-  
 861 specific VoC peptide pools or equivalent peptide pools with corresponding Wuhan aa sequences, that  
 862 is, reference pool (Ref). (A) Variant B.1.1.7, (B) Variant B.1.3.5.1, (C) Variant P.1 and (D) Variant  
 863 B.1.617.2.

864



866 **Figure S9. Flow cytometry data gating strategy for Variants of Concern (VoC)-spike-specific**  
 867 **intracellular cytokine (ICS) assay for CD8 T cells.**

868 Representative strategy to measure Variants of Concern (VoC)-spike-specific CD8 T cells via  
 869 percentage of intracellular cytokines: perforin (PRF1), Tumour Necrosis Factor alpha (TNFα),  
 870 Granzyme B (GZMB), IL-2 and Interferon gamma (IFN-γ). PBMC were stimulated with either VoC-  
 871 specific VoC peptide pools or equivalent peptide pools with corresponding Wuhan aa sequences, that  
 872 is, reference pool (Ref). (A) Variant B.1.1.7, (B) Variant B.1.3.5.1, (C) Variant P.1 and (D) Variant  
 873 B.1.617.2.

874

## 875 References

- 876 1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of  
877 probable bat origin. *Nature* 2020; **579**(7798): 270-3.
- 878 2. Huang X, Shao X, Xing L, Hu Y, Sin DD, Zhang X. The impact of lockdown timing on COVID-19  
879 transmission across US counties. *EClinicalMedicine* 2021; **38**: 101035.
- 880 3. Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national  
881 immunization program in Israel. *Nature medicine* 2021; **27**(6): 1055-61.
- 882 4. Barandalla I, Alvarez C, Barreiro P, de Mendoza C, González-Crespo R, Soriano V. Impact of  
883 scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. *International Journal of*  
884 *Infectious Diseases* 2021.
- 885 5. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2  
886 infections in the United Kingdom. *Nature medicine* 2021; **27**(8): 1370-8.
- 887 6. Bahl A, Johnson S, Maine G, et al. Vaccination reduces need for emergency care in  
888 breakthrough COVID-19 infections: A multicenter cohort study. *Lancet Regional Health Americas*  
889 2021: 100065.
- 890 7. Doroshenko A. The Combined Effect of Vaccination and Nonpharmaceutical Public Health  
891 Interventions—Ending the COVID-19 Pandemic. *JAMA Network Open* 2021; **4**(6): e2111675-e.
- 892 8. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections.  
893 *Nature communications* 2021; **12**(1): 63.
- 894 9. Li C, Yu D, Wu X, et al. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding  
895 domain among COVID-19 convalescent plasma donors in Wuhan. *Nature communications* 2021; **12**(1):  
896 4144.
- 897 10. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after  
898 six months: a longitudinal prospective study. *The Lancet regional health Europe* 2021: 100208.
- 899 11. Israel A, Shenhar Y, Green I, et al. Large-scale study of antibody titer decay following  
900 BNT162b2 mRNA vaccine or SARS-CoV-2 infection. *medRxiv* 2021: 2021.08.19.21262111.
- 901 12. Liu Y, Liu J, Xia H, et al. Neutralizing Activity of BNT162b2-Elicited Serum. *The New England*  
902 *journal of medicine* 2021; **384**(15): 1466-8.
- 903 13. Hammerschmidt SI, Bosnjak B, Bernhardt G, et al. Neutralization of the SARS-CoV-2 Delta  
904 variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. *Cellular &*  
905 *molecular immunology* 2021.
- 906 14. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to  
907 antibody neutralization. *Nature* 2021; **596**(7871): 276-80.
- 908 15. Davis C, Logan N, Tyson G, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2  
909 variant of concern following vaccination. *medRxiv* 2021: 2021.06.23.21259327.
- 910 16. Shen X, Tang H, Pajon R, et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. *The*  
911 *New England journal of medicine* 2021; **384**(24): 2352-4.
- 912 17. Yadav PD, Sapkal GN, Ella R, et al. Neutralization of Beta and Delta variant with sera of COVID-  
913 19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. *Journal of Travel*  
914 *Medicine* 2021.
- 915 18. Bates TA, Leier HC, Lyski ZL, et al. Neutralization of SARS-CoV-2 variants by convalescent and  
916 BNT162b2 vaccinated serum. *Nature communications* 2021; **12**(1): 5135.
- 917 19. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the  
918 B.1.351 Variant. *The New England journal of medicine* 2021; **384**(20): 1899-909.
- 919 20. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and  
920 immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *Cell Reports Medicine* 2021; **2**(2):  
921 100204.
- 922 21. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and  
923 Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell host*  
924 *& microbe* 2020; **27**(4): 671-80 e2.

- 925 22. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8  
926 months after infection. *Science* 2021.
- 927 23. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus  
928 in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 2020; **181**(7): 1489-501 e15.
- 929 24. Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 Human T cell Epitopes: adaptive immune response  
930 against COVID-19. *Cell host & microbe* 2021.
- 931 25. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+  
932 T cell reactivity in infected or vaccinated individuals. *Cell Reports Medicine* 2021; **2**(7): 100355.
- 933 26. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral  
934 but not T-cell responses in COVID-19 convalescent donors and vaccinees. *Science immunology* 2021;  
935 **6**(59).
- 936 27. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-  
937 19 and SARS, and uninfected controls. *Nature* 2020; **584**(7821): 457-62.
- 938 28. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster against  
939 Covid-19 in Israel. *The New England journal of medicine* 2021.
- 940 29. van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. *Nature Materials* 2020;  
941 **19**(8): 810-2.
- 942 30. Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and  
943 unknowns of antigen presentation and modes of action. *npj Vaccines* 2021; **6**(1): 104.
- 944 31. Australia GoS. 2021. <https://www.covid-19.sa.gov.au/home/dashboard> (accessed  
945 07/04/2021).
- 946 32. Ryan FJ, Hope CM, Masavuli MG, et al. Long-term perturbation of the peripheral immune  
947 system months after SARS-CoV-2 infection. *medRxiv* 2021: 2021.07.30.21261234.
- 948 33. Hope CM, Welch J, Mohandas A, et al. Peptidase inhibitor 16 identifies a human regulatory T-  
949 cell subset with reduced FOXP3 expression over the first year of recent onset type 1 diabetes.  
950 *European journal of immunology* 2019; **49**(8): 1235-50.
- 951 34. Hsieh CL, Goldsmith JA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-  
952 CoV-2 spikes. *Science* 2020; **369**(6510): 1501-5.
- 953 35. Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2  
954 seroconversion in humans. *Nature medicine* 2020; **26**(7): 1033-6.
- 955 36. Abayasingam A, Balachandran H, Agapiou D, et al. Long-term persistence of RBD(+) memory  
956 B cells encoding neutralizing antibodies in SARS-CoV-2 infection. *Cell reports Medicine* 2021; **2**(4):  
957 100228.
- 958 37. Hoffmann M, Kleine-Weber H, Pohlmann S. A Multibasic Cleavage Site in the Spike Protein of  
959 SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* 2020; **78**(4): 779-84 e5.
- 960 38. Keck ZY, Li SH, Xia J, et al. Mutations in hepatitis C virus E2 located outside the CD81 binding  
961 sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. *J Virol* 2009;  
962 **83**(12): 6149-60.
- 963 39. Bartosch B, Bukh J, Meunier JC, et al. In vitro assay for neutralizing antibody to hepatitis C  
964 virus: evidence for broadly conserved neutralization epitopes. *Proc Natl Acad Sci U S A* 2003; **100**(24):  
965 14199-204.
- 966 40. Kalempera MD, Cappella-Pujol J, Chumbe A, et al. Optimised cell systems for the investigation  
967 of hepatitis C virus E1E2 glycoproteins. *bioRxiv* 2020: 2020.06.18.159442.
- 968 41. Crawford KHD, Eguia R, Dingens AS, et al. Protocol and Reagents for Pseudotyping Lentiviral  
969 Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* 2020; **12**(5).
- 970 42. Hoaglin DC. Revising a display of multidimensional laboratory measurements to improve  
971 accuracy of perception. *Methods Inf Med* 1993; **32**(5): 418-20.
- 972 43. Tea F, Ospina Stella A, Aggarwal A, et al. SARS-CoV-2 neutralizing antibodies: Longevity,  
973 breadth, and evasion by emerging viral variants. *PLoS medicine* 2021; **18**(7): e1003656.
- 974 44. Carrasco Pro S, Sidney J, Paul S, et al. Automatic Generation of Validated Specific Epitope Sets.  
975 *Journal of immunology research* 2015; **2015**: 763461.

- 976 45. Le NPK, Herz C, Gomes JVD, et al. Comparative Anti-Inflammatory Effects of Salix Cortex  
977 Extracts and Acetylsalicylic Acid in SARS-CoV-2 Peptide and LPS-Activated Human In Vitro Systems.  
978 *International journal of molecular sciences* 2021; **22**(13).
- 979 46. Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable  
980 memory enhanced by cross-reactive T cells. *Science* 2021; **374**(6566): eabj9853.
- 981 47. Abayasingam A, Balachandran H, Agapiou D, et al. Long-term persistence of RBD-positive  
982 memory B cells encoding neutralising antibodies in SARS-CoV-2 infection. *Cell reports Medicine* 2021:  
983 100228.
- 984 48. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* 2021; **184**(4): 861-80.
- 985 49. Saini SK, Hersby DS, Tamhane T, et al. SARS-CoV-2 genome-wide T cell epitope mapping  
986 reveals immunodominance and substantial CD8(+) T cell activation in COVID-19 patients. *Science*  
987 *immunology* 2021; **6**(58).
- 988 50. Jung JH, Rha M-S, Sa M, et al. SARS-CoV-2-specific T cell memory is sustained in COVID-19  
989 convalescent patients for 10 months with successful development of stem cell-like memory T cells.  
990 *Nature communications* 2021; **12**(1): 4043.
- 991 51. Kumar BV, Connors TJ, Farber DL. Human T Cell Development, Localization, and Function  
992 throughout Life. *Immunity* 2018; **48**(2): 202-13.
- 993 52. Juno JA, Tan HX, Lee WS, et al. Humoral and circulating follicular helper T cell responses in  
994 recovered patients with COVID-19. *Nature medicine* 2020; **26**(9): 1428-34.
- 995 53. Vitale J, Mumoli N, Clerici P, et al. Assessment of SARS-CoV-2 Reinfection 1 Year After Primary  
996 Infection in a Population in Lombardy, Italy. *JAMA internal medicine* 2021.
- 997 54. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2  
998 Infection in Health Care Workers. *The New England journal of medicine* 2021; **384**(6): 533-40.
- 999 55. Hall VJ, Foulkes S, Charlett A, et al. SARS-CoV-2 infection rates of antibody-positive compared  
1000 with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study  
1001 (SIREN). *Lancet* 2021; **397**(10283): 1459-69.
- 1002 56. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-  
1003 moderate COVID-19. *Nature communications* 2021; **12**(1): 1162.
- 1004 57. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of  
1005 immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine* 2021.
- 1006 58. Deng W, Bao L, Liu J, et al. Primary exposure to SARS-CoV-2 protects against reinfection in  
1007 rhesus macaques. *Science* 2020; **369**(6505): 818-23.
- 1008 59. Townsend JP, Hassler HB, Wang Z, et al. The durability of immunity against reinfection by  
1009 SARS-CoV-2: a comparative evolutionary study. *The Lancet Microbe* 2021.
- 1010 60. Gasser R, Cloutier M, Prevost J, et al. Major role of IgM in the neutralizing activity of  
1011 convalescent plasma against SARS-CoV-2. *Cell reports* 2021; **34**(9): 108790.
- 1012 61. Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape &in vitro&in vitro  
1013 from a highly neutralizing COVID-19 convalescent plasma. *bioRxiv* 2020: 2020.12.28.424451.
- 1014 62. Liu C, Ginn HM, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine  
1015 and convalescent serum. *Cell* 2021; **184**(16): 4220-36 e13.
- 1016 63. Gordon CL, Miron M, Thome JJC, et al. Tissue reservoirs of antiviral T cell immunity in  
1017 persistent human CMV infection. *Journal of Experimental Medicine* 2017; **214**(3): 651-67.
- 1018 64. Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory  
1019 to SARS-CoV-2 and variants of concern. *Science* 2021: eabm0829.
- 1020 65. Collins DR, Gaiha GD, Walker BD. CD8+ T cells in HIV control, cure and prevention. *Nature*  
1021 *Reviews Immunology* 2020; **20**(8): 471-82.
- 1022 66. Ciurea A, Hunziker L, Martinic MMA, Oxenius A, Hengartner H, Zinkernagel RM. CD4+ T-cell-  
1023 epitope escape mutant virus selected in vivo. *Nature medicine* 2001; **7**(7): 795-800.
- 1024 67. Price GE, Ou R, Jiang H, Huang L, Moskophidis D. Viral escape by selection of cytotoxic T cell-  
1025 resistant variants in influenza A virus pneumonia. *The Journal of experimental medicine* 2000; **191**(11):  
1026 1853-67.

- 1027 68. Uebelhoer L, Han JH, Callendret B, et al. Stable cytotoxic T cell escape mutation in hepatitis C  
1028 virus is linked to maintenance of viral fitness. *PLoS pathogens* 2008; **4**(9): e1000143.
- 1029 69. CH B, al e. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like  
1030 Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States,  
1031 January–September 2021. CDC website: Centre for Disease Control and Prevention 2021.
- 1032 70. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With  
1033 Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *Jama* 2021.
- 1034 71. Organization WH. COVID-19 Dashboard. 2021.
- 1035 72. Uriu K, Kimura I, Shirakawa K, et al. Neutralization of the SARS-CoV-2 Mu Variant by  
1036 Convalescent and Vaccine Serum. *New England Journal of Medicine* 2021.
- 1037 73. Bugembe DL, Phan MVT, Ssewanyana I, et al. Emergence and spread of a SARS-CoV-2 lineage  
1038 A variant (A.23.1) with altered spike protein in Uganda. *Nature microbiology* 2021; **6**(8): 1094-101.
- 1039